Cash/Burn From SEC Filing For Period: 

Q1 '20

CARA

Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).

Cash

$120.2M

Burn Rate

-$28.9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Korsuva IV (CR845 IV)

Pruritus CKD-HD

NDA Submission

H2 2020

Oral Korsuva

Pruritus CKD 3-5

Phase 3 TBA

H2 2020

Oral Korsuva

Atopic Dermatitis

Phase 2 (Top-line results)

H2 2020

Oral Korsuva

Pruritus CLD

Phase 2 Topline Data

H2 2020

Recent Posts

See What The Community Is Saying - Click To See Full Post

Educational video - Near-term ...

Check out my recent video in our educational forum, which discusses the unfortunate reality of small and mid-cap biopharma investing: near-term dilution. Case studies are provided for CARA and TGTX, ...

CARA DD Update...

Summary 2020 is a big year for oral Korsuva. CARA took a big hit in late 2019 from oral phase 2 data. The second phase 3 readout for IV Korsuva, KALM-II, is set to report out in Q2 ‘20. Overview Cara...

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon